Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23435612 | 0.74 | HTR2A (0.33) | — | |
| SCHEMBL477075 | 0.70 | — | — | |
| SCHEMBL9416877 | 0.67 | — | — | |
| SCHEMBL3712450 | 0.64 | — | — | |
| SCHEMBL29137617 | 0.60 | NISCH (0.38) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL29157648 | 0.59 | — | — | |
| SCHEMBL16237824 | 0.57 | CHRNB2 (0.34) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL6445267 | 0.57 | CHRNB2 (0.34) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL16237326 | 0.57 | CHRNB2 (0.34) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL16496273 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | disclosed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | NR3C1, CNKSR1, NR3C2 | CHRM5 202/4885CHRM3 211/4885CHRM2 251/4885 |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TLR7, IFNAR1, CBR3 | CHRM5 213/4885CHRM3 356/4885CHRM2 71/4885 |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | CHRM5 1951/4885CHRM3 1439/4885CHRM2 1507/4885 |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CHRM5 369/4885CHRM3 516/4885CHRM2 193/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | CHRM5 214/4885CHRM3 389/4885CHRM2 76/4885 |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CHRM5 369/4885CHRM3 516/4885CHRM2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.